|
Zdravljenje z bisfosfonati pride v poštev pri bolnikih z izrazitim znižanjem kostne mase in zlomi (20, 21). Po priporočilih Ameriškega združenja za cistično fibrozo sodijo v to skupino bolnikih, pri katerih je kostna gostota v predelu ledvenega dela hrbtenice ali levega kolka znižana bolj kot dva standardna odklona od povprečja (t score < -2) in pri tistih, pri katerih je kostna gostota med –1.0 in –2.0 standardnimi odkloni pa če imajo zlome, se kostna gostota zmanjšuje za več kot 3% do 5% letno, če je pri njih je predvideno dalj časa trajajoče peroralno zdravljenje s kortikosteroidi ali pa presaditev pljuč (10).
Sladkorna bolezen in zmanjšanje mineralne gostote pri bolnikih s CF lahko dolgoročno resno ogrozita zdravje in preživetje teh bolnikov, zato je potrebno redno spremljanje ter pravočasno in ustrezno ukrepanje.
LITERATURA
1. Rosenecker J, Eichler L, Kuhn L, Harms HK, von der Hardt J. Genetic determination of diabetes mellitus in patients with cystic fibrosis. J Pediatr 1995;127:441-3.
2. Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr 1999; 88: 389-93.
3. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998;133:10-7.
4. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: a five-year prospective study. Br Med J 1995;311:655-8.
5. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz C, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus. A consenus conference report. Diab Res Clin Pract 1999; 45: 61-73.
6. Tofé S, Moreno JC, Máiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 2005; 152:241.
7. Dobsin L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycemia in cystic fibrosis patients. Diabet Med 2004;21:691-6.
8. Sulli N, Bertasi S, Zullo S, Shasaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. J Cyst Fibros 2006 (Epub ahead of print).
9. Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA. Increased Rate of Fractures and Severe Kyphosis: Sequelae of Living into Adulthood with Cystic Fibrosis. Ann Intern Med 1998; 128: 186-93.
10. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Consensus statement: Guide to Bone Health and Disease in cystic Fibrosis. J Clin Endocrinol Metab 2005; 90: 1888-96.
11. Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith AH, Haigh I. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax; 2000: 55:798-804.
12. Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, Niven R McL, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54: 961-7.
13. Aris RM, Stephens AR, Ontjes DA, Blackwood AD, Lark RK, Hensler MB, et al. Adverse Alterations in Bone Metabolism Are Associated with Lung Infection in Adults with Cystic Fibrosis. Amm J Respir Crit Care Med 2000; 162: 1674-8.
14. Street ME, Ziveri MA, Spaggiari C, Viani I, Volta C, Grzincich GL, et al. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol 2006; 154: 47-52.
15. Bianchi ML, Romano G, Saraifoger S, Constantini D, Limonta C, Colombo C. BMD and body composition in children and young patients affected by cystic fibrosis. J Bone Miner Res 2006; 21: 388-96.
16. Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G. Severe osteopenia in CFTR-null mice. Bone 2004; 35: 595-603.
17. Rovner AJ, Stallings VA, Schall JI, Leonard MB, Zemel BS. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr 2007; 86: 1694-9.
18. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T,et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of multicenter randimized controlled trial. J Clin Endocrinol Metab 2006; 91: 4925-9.
19. Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK. Effect of intravenuous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56: 314-6.
20. Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, et al. Efficacy of Alendronate in Adults with Cystic Fibrosis with Low bone Density. Am J Resp Critical Care Med 2004; 169: 77-82.
==Crtomir Iglic, Klemen Jenko==
|
